BMPR2 and pulmonary arterial hypertension: In addition, children with PAH and BMPR2 mutations are unlikely to respond to vasodilators, and it is impossible for them to gain benefit from treatment of calcium channel blockade (Elliott et al., 2006; Rosenzweig et al., 2008).